← back to search

Guy Aumais

Hôpital Maisonneuve-Rosemont · CA
Area of research
Genetics · Molecular Biology
Research interest
Research interests include Inflammatory Bowel Disease, Gut microbiota and health, Microscopic Colitis, and Helicobacter pylori-related gastroenterology studies.
h-index
26
citations
3,317
works
88
NIH funding
primary concept
Medicine
email

Recent publications

Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease
Gut Microbes 2025cited by 3position: middledoi
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
The Lancet 2024cited by 75position: middledoi
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn’s Disease
Gastroenterology 2024cited by 20position: middledoi
Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives
Gastroenterology 2023cited by 186position: middledoi
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis
Gastroenterology 2023cited by 86position: middledoi
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis
Gut 2023cited by 71position: middledoi
HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
Gastroenterology 2023cited by 16position: middledoi
Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn’s Disease
Gastroenterology 2022cited by 188position: middledoi
Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation
Gastroenterology 2022cited by 110position: middledoi
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
˜The œLancet. Gastroenterology & hepatology 2021cited by 92position: middledoi
Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk
Gastroenterology 2021cited by 74position: middledoi
Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease
Gastroenterology 2020cited by 302position: middledoi
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data
Scientific Reports 2019cited by 106position: middledoi
Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn’s Disease
Inflammatory Bowel Diseases 2019cited by 26position: middledoi
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
Nature Communications 2018cited by 248position: middledoi
A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition
Gastroenterology 2016cited by 152position: middledoi
The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease
Clinical Gastroenterology and Hepatology 2014cited by 227position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux3 papers (2014–2025)Alain Bitton · McGill University Health Centre3 papers (2014–2025)A. Hillary Steinhart · Lunenfeld-Tanenbaum Research Institute3 papers (2014–2025)Dan Turner · Oxford Nanopore Technologies (United Kingdom)2 papers (2021–2025)Sun-Ho Lee · Asan Medical Center2 papers (2021–2025)Maria Cino · University Health Network2 papers (2021–2025)Mark S. Silverberg · Queen's University2 papers (2021–2025)Williams Turpin · UMR QualiSud2 papers (2021–2025)Haim Leibovitzh · Tel Aviv University2 papers (2021–2025)Çharles N. Bernstein · University of Manitoba2 papers (2014–2025)Osvaldo Espin‐Garcia · University Health Network2 papers (2021–2025)Kenneth Croitoru · Sinai Health System2 papers (2021–2025)Karen Madsen · University of Alberta2 papers (2014–2025)Kevan Jacobson · Immune Deficiency Foundation2 papers (2021–2025)Colette Deslandres · Centre Hospitalier Universitaire Sainte-Justine2 papers (2021–2025)Paul Moayyedi · McMaster University2 papers (2021–2025)Anne M. Griffiths · SickKids Foundation2 papers (2021–2025)Paolo Gionchetti · Istituti di Ricovero e Cura a Carattere Scientifico1 papers (2014–2014)Mingyue Xue · Affiliated Hospital of Nantong University1 papers (2025–2025)Alaa Rostom · National University Hospital1 papers (2014–2014)